^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable                        Subject'
dose of      dose of                          s type
SSRI/SNRI  SSRI/SNRI  Subject's type        of visit
EDC          EDC (N)  of visit                   (N)      SITE
                                            Analysis
                                            Sequence
  site_n      trtn  trt            SITEIDN    Number
                Planned                   Actual  Analysis
Planned       Treatment  Actual        Treatment     Visit
Treatment           (N)  Treatment           (N)       (N)
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                      Analysis
                                        Window
Analysis         Visit                   Visit  Analysis
Visit           Number  Visit              (N)  Window Visit
                                                     Baseline
Parameter                                            Record
Code       Parameter                                 Flag
                     Analysis  Analysis
Analaysis  Analysis     Date/  Relative  Parameter
     Date      Time      Time       Day  Category 1
                                                  Change
Parameter     Analysis  Analysis      Baseline      from
Category 2       Value  Value (C)        Value  Baseline
Percentage   Duration
    Change         of  Time-Dependent  Time-Dependent
      from  Treatment       covariate       covariate
  Baseline   in Weeks      for Week 1      for Week 4
                                              Criterion
                                              1
Time-Dependent  Time-Dependent                Evaluation
     covariate   covariate for  Analysis      Result
    for Week 8         Week 12  Criterion 1   Flag
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              Criterion                 Criterion
              2                         3
              Evaluation                Evaluation
Analysis      Result      Analysis      Result      Analysis
Criterion 2   Flag        Criterion 3   Flag        Criterion 4
Criterion
4
Evaluation  Analysis  Analysis  Analysis
Result      Record    Record    Record
Flag        Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1063-1001                    
10631001                                          
1063                  USA      1987-03-10          35  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               10631001/35/
                                                    F/W         
35/F             35/W/F      
Hispanic or Latino                                          1
    88.5     170.2      31.2  2022-08-17  2022-08-17  2022-09-14
2022-11-06  2022-09-14  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  14SEP2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1987-03-10  Charles (Brendan) Montano      ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          N                        2
Absence                              2  No                 2
No                 2                                      1063
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       1         3  Placebo              1       363
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22901     40440  1.9787E9        -1  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    8               0               0
             0               1                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1063-1002                    
10631002                                          
1063                  USA      1997-07-22          25  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               10631002/25/
                                                    F/W         
25/F             25/W/F      
Non-Hispanic or Latino                                      2
    71.2     157.5      28.0  2022-09-12  2022-09-12  2022-10-04
2022-11-06  2022-10-04  2022-11-06  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  04OCT2022
mg                       mg                                
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1997-07-22  Charles (Brendan) Montano      ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Presence                             1  Yes                1
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Yes                1                                      1063
       1         1  JZP150 0.3           1       363
                    mg                              
JZP150 0.3            1  JZP150 0.3            1         0
mg                       mg                               
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22921     36840  1.9804E9        -1  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    5               0               0
             1               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1063-1003                    
10631003                                          
1063                  USA      2001-06-28          21  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
BLACK OR AFRICAN AMERICAN                           10631003/21/
                                                    F/B         
21/F             21/B/F      
Hispanic or Latino                                          1
    57.2     154.9      21.5  2022-09-19  2022-09-19  2022-10-14
2022-11-06  2022-10-14  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  14OCT2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
2001-06-28  Charles (Brendan) Montano      ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Presence                             1  Yes                1
Yes                1                                      1063
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       1         3  Placebo              1       182
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22930     51720  1.9812E9        -2  PGI         
POST-                5  VERY SEVERE          5          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    3               0               1
             2               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable                        Subject'
dose of      dose of                          s type
SSRI/SNRI  SSRI/SNRI  Subject's type        of visit
EDC          EDC (N)  of visit                   (N)      SITE
                                            Analysis
                                            Sequence
  site_n      trtn  trt            SITEIDN    Number
                Planned                   Actual  Analysis
Planned       Treatment  Actual        Treatment     Visit
Treatment           (N)  Treatment           (N)       (N)
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                      Analysis
                                        Window
Analysis         Visit                   Visit  Analysis
Visit           Number  Visit              (N)  Window Visit
                                                     Baseline
Parameter                                            Record
Code       Parameter                                 Flag
                     Analysis  Analysis
Analaysis  Analysis     Date/  Relative  Parameter
     Date      Time      Time       Day  Category 1
                                                  Change
Parameter     Analysis  Analysis      Baseline      from
Category 2       Value  Value (C)        Value  Baseline
Percentage   Duration
    Change         of  Time-Dependent  Time-Dependent
      from  Treatment       covariate       covariate
  Baseline   in Weeks      for Week 1      for Week 4
                                              Criterion
                                              1
Time-Dependent  Time-Dependent                Evaluation
     covariate   covariate for  Analysis      Result
    for Week 8         Week 12  Criterion 1   Flag
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              Criterion                 Criterion
              2                         3
              Evaluation                Evaluation
Analysis      Result      Analysis      Result      Analysis
Criterion 2   Flag        Criterion 3   Flag        Criterion 4
Criterion
4
Evaluation  Analysis  Analysis  Analysis
Result      Record    Record    Record
Flag        Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1160-1002                    
11601002                                          
1160                  USA      1982-07-16          40  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               11601002/40/
                                                    F/W         
40/F             40/W/F      
Non-Hispanic or Latino                                      2
    89.5     164.0      33.2  2022-07-25  2022-07-25  2022-08-02
2022-08-18  2022-08-02  2022-08-18  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  02AUG2022
18AUG2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1982-07-16  Muhammad Saleem Ismail         DISCONTINUED
18AUG2022  ADVERSE EVENT                                     
AE001-        DISCONTINUED                                      
INCREASING                                                      
DEPRESSION                                                      
SYMPTOMS-18                                                     
AUG                                                             
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

2022;SUBJECT                                                    
REPORTED                                                        
INCREASED                                                       
DEPRESSION                                                      
AND TIME                                                        
CONSTRAINTS                                                     
WITH NEW JOB                                                    
WITHDRAWAL    TIME                                        
OF CONSENT    CONSTRAINTS                                 
BY STUDY      AT WORK AND                                 
PARTICIPANT   SUBJECT                                     
              EXPERIENCED                                 
              HIGH AND                                    
              LOWS SINCE                                  
              STARTING IP                                 
N          N          Y                        1
Absence                              2  No                 2
No                 2                                      1160
       2         3  Placebo              2       182
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22858     43740   1.975E9        -1  PGI         
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

POST-                2  MILD                 2          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    2               0               1
             2               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1160-1006                    
11601006                                          
1160                  USA      1965-03-03          57  YEARS
<=65 years                                                 1
>45 years                                                  2
M           1
BLACK OR AFRICAN AMERICAN                           11601006/57/
                                                    M/B         
57/M             57/B/M      
Non-Hispanic or Latino                                      2
   116.9     184.5      34.6  2022-09-13  2022-09-13  2022-09-27
2022-10-04  2022-09-27  2022-10-04  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  27SEP2022
04OCT2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1965-03-03  Muhammad Saleem Ismail         ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N                                    
Absence                              2  No                 2
No                 2                                      1160
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       2         3  Placebo              2       363
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22914     39480  1.9798E9        -1  PGI         
POST-                2  MILD                 2          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    1               0               1
             2               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1160-1007                    
11601007                                          
1160                  USA      1958-06-15          64  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               11601007/64/
                                                    F/W         
64/F             64/W/F      
Non-Hispanic or Latino                                      2
    71.5     157.5      28.5  2022-10-10  2022-10-10  2022-10-21
2022-11-06  2022-10-21  2022-11-06  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  21OCT2022
mg                       mg                                
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1958-06-15  Muhammad Saleem Ismail         ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          N                        2
Presence                             1  Yes                1
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Yes                1                                      1160
       2         1  JZP150 0.3           2       182
                    mg                              
JZP150 0.3            1  JZP150 0.3            1         0
mg                       mg                               
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22938     40200  1.9819E9        -1  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    2               0               1
             2               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable                        Subject'
dose of      dose of                          s type
SSRI/SNRI  SSRI/SNRI  Subject's type        of visit
EDC          EDC (N)  of visit                   (N)      SITE
                                            Analysis
                                            Sequence
  site_n      trtn  trt            SITEIDN    Number
                Planned                   Actual  Analysis
Planned       Treatment  Actual        Treatment     Visit
Treatment           (N)  Treatment           (N)       (N)
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                      Analysis
                                        Window
Analysis         Visit                   Visit  Analysis
Visit           Number  Visit              (N)  Window Visit
                                                     Baseline
Parameter                                            Record
Code       Parameter                                 Flag
                     Analysis  Analysis
Analaysis  Analysis     Date/  Relative  Parameter
     Date      Time      Time       Day  Category 1
                                                  Change
Parameter     Analysis  Analysis      Baseline      from
Category 2       Value  Value (C)        Value  Baseline
Percentage   Duration
    Change         of  Time-Dependent  Time-Dependent
      from  Treatment       covariate       covariate
  Baseline   in Weeks      for Week 1      for Week 4
                                              Criterion
                                              1
Time-Dependent  Time-Dependent                Evaluation
     covariate   covariate for  Analysis      Result
    for Week 8         Week 12  Criterion 1   Flag
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              Criterion                 Criterion
              2                         3
              Evaluation                Evaluation
Analysis      Result      Analysis      Result      Analysis
Criterion 2   Flag        Criterion 3   Flag        Criterion 4
Criterion
4
Evaluation  Analysis  Analysis  Analysis
Result      Record    Record    Record
Flag        Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1303-1001                    
13031001                                          
1303                  USA      1982-02-15          40  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
BLACK OR AFRICAN AMERICAN                           13031001/40/
                                                    F/B         
40/F             40/B/F      
Non-Hispanic or Latino                                      2
    80.6     167.6      28.2  2022-04-28  2022-04-28  2022-05-14
2022-08-05  2022-05-14  2022-09-16  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  14MAY2022
05AUG2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1982-02-15  Olga Lapeyra                   COMPLETED   
16SEP2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2  On-site                      1      1303
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       3         3  Placebo              3       548
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22778     46620  1.9681E9        -1  PGI         
POST-                2  MILD                 2          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1303-1001                    
13031001                                          
1303                  USA      1982-02-15          40  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
BLACK OR AFRICAN AMERICAN                           13031001/40/
                                                    F/B         
40/F             40/B/F      
Non-Hispanic or Latino                                      2
    80.6     167.6      28.2  2022-04-28  2022-04-28  2022-05-14
2022-08-05  2022-05-14  2022-09-16  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  14MAY2022
05AUG2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1982-02-15  Olga Lapeyra                   COMPLETED   
16SEP2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2  On-site                      1      1303
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       3         3  Placebo              3       552
Placebo               3  Placebo               3        12
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22862     43500  1.9753E9        84  PGI         
POST-                3  MODERATE             2         1
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
        50         12               0               0
             0               0                          
                                                    = 1 unit of 
                                                    improvement 
                                                    on the PGI-S
                                                    from        
                                                    Baseline to 
                                                    Week 12     
Y           Y                   Y       
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1303-1002                    
13031002                                          
1303                  USA      1994-07-08          28  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               13031002/28/
                                                    F/W         
28/F             28/W/F      
Non-Hispanic or Latino                                      2
    69.4     160.0      27.1  2022-08-19  2022-08-19  2022-09-13
2022-11-06  2022-09-13  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  13SEP2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1994-07-08  Olga Lapeyra                   ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2                                      1303
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       3         3  Placebo              3       363
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                                    
    22901     37620  1.9787E9         1  PGI         
POST-                3  MODERATE                        
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    8               0               0
             0               1                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1303-1004                    
13031004                                          
1303                  USA      1961-01-04          61  YEARS
<=65 years                                                 1
>45 years                                                  2
M           1
WHITE                                               13031004/61/
                                                    M/W         
61/M             61/W/M      
Non-Hispanic or Latino                                      2
    76.6     178.0      24.9  2022-09-21  2022-09-21  2022-10-14
2022-11-06  2022-10-14  2022-11-06  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  14OCT2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1961-01-04  Olga Lapeyra                   ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N                                    
Absence                              2  No                 2
No                 2                                      1303
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       3         2  JZP150 4 mg          3       182
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22930     40200  1.9812E9        -2  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    3               0               1
             2               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable                        Subject'
dose of      dose of                          s type
SSRI/SNRI  SSRI/SNRI  Subject's type        of visit
EDC          EDC (N)  of visit                   (N)      SITE
                                            Analysis
                                            Sequence
  site_n      trtn  trt            SITEIDN    Number
                Planned                   Actual  Analysis
Planned       Treatment  Actual        Treatment     Visit
Treatment           (N)  Treatment           (N)       (N)
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                      Analysis
                                        Window
Analysis         Visit                   Visit  Analysis
Visit           Number  Visit              (N)  Window Visit
                                                     Baseline
Parameter                                            Record
Code       Parameter                                 Flag
                     Analysis  Analysis
Analaysis  Analysis     Date/  Relative  Parameter
     Date      Time      Time       Day  Category 1
                                                  Change
Parameter     Analysis  Analysis      Baseline      from
Category 2       Value  Value (C)        Value  Baseline
Percentage   Duration
    Change         of  Time-Dependent  Time-Dependent
      from  Treatment       covariate       covariate
  Baseline   in Weeks      for Week 1      for Week 4
                                              Criterion
                                              1
Time-Dependent  Time-Dependent                Evaluation
     covariate   covariate for  Analysis      Result
    for Week 8         Week 12  Criterion 1   Flag
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              Criterion                 Criterion
              2                         3
              Evaluation                Evaluation
Analysis      Result      Analysis      Result      Analysis
Criterion 2   Flag        Criterion 3   Flag        Criterion 4
Criterion
4
Evaluation  Analysis  Analysis  Analysis
Result      Record    Record    Record
Flag        Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1358-1001                    
13581001                                          
1358                  USA      1974-12-10          47  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               13581001/47/
                                                    F/W         
47/F             47/W/F      
Non-Hispanic or Latino                                      2
    64.0     163.8      24.0  2021-12-29  2021-12-29  2022-01-20
2022-01-28  2022-01-20  2022-02-01  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  20JAN2022
28JAN2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1974-12-10  Elias Sarkis                   DISCONTINUED
01FEB2022  WITHDRAWAL BY PARTICIPANT                         
W/D OF        DISCONTINUED                                      
CONSENT BY                                                      
STUDY                                                           
PARTICIPANT                                                     
WITHDRAWAL    W/D OF                                      
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

OF CONSENT    CONSENT BY                                  
BY STUDY      STUDY                                       
PARTICIPANT   PARTICIPANT                                 
N          N          Y                        1
Absence                              2  No                 2
No                 2                                      1358
       4         3  Placebo              4       363
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22664     42120  1.9582E9        -1  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    1               0               1
             2               2                          
                                                                
            Y                   Y       
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1358-1010                    
13581010                                          
1358                  USA      1967-08-20          54  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               13581010/54/
                                                    F/W         
54/F             54/W/F      
Non-Hispanic or Latino                                      2
    70.8     170.2      26.0  2022-05-06  2022-05-06  2022-05-21
2022-06-02  2022-05-21  2022-06-20  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  21MAY2022
02JUN2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1967-08-20  Elias Sarkis                   DISCONTINUED
20JUN2022  WITHDRAWAL BY PARTICIPANT                         
UNABLE TO     DISCONTINUED                                      
CONTINUE                                                        
CLINIC VISIT                                                    
SCHEDULE PER                                                    
SUBJECT                                                         
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

WITHDRAWAL    SUBJECT ET                                  
OF CONSENT    AND WITHDREW                                
BY STUDY      CONSENT ON                                  
PARTICIPANT   20 JUN 2022                                 
              DUE TO                                      
              "UNABLE TO                                  
              MEET STUDY                                  
              VISIT                                       
              REQUIREMENTS                                
              ."                                          
N          N          N                        2
Absence                              2  No                 2
No                 2                                      1358
       4         3  Placebo              4       182
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22785     36480  1.9687E9        -1  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    2               0               1
             2               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1358-1014                    
13581014                                          
1358                  USA      2000-05-23          22  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               13581014/22/
                                                    F/W         
22/F             22/W/F      
Hispanic or Latino                                          1
    50.8     153.7      21.3  2022-06-07  2022-06-07  2022-07-06
2022-07-11  2022-07-06  2022-07-14  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  06JUL2022
11JUL2022  Y           Y                                 
Y           Y           Y         Y         N          N        
2000-05-23  Elias Sarkis                   DISCONTINUED
14JUL2022  ADVERSE EVENT                                     
AE001-"       DISCONTINUED                                      
EXTREMELY                                                       
DROWSY"-06                                                      
JUL 2022                                                        
ADVERSE       AE001-"                                     
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

EVENT         EXTREMELY                                   
              DROWSY"-06                                  
              JUL 2022                                    
N          N          Y                        1
Absence                              2  No                 2
No                 2                                      1358
       4         3  Placebo              4       362
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22831     50100  1.9726E9        -1  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    1               0               1
             2               2                          
                                                                
            Y                   Y       
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable                        Subject'
dose of      dose of                          s type
SSRI/SNRI  SSRI/SNRI  Subject's type        of visit
EDC          EDC (N)  of visit                   (N)      SITE
                                            Analysis
                                            Sequence
  site_n      trtn  trt            SITEIDN    Number
                Planned                   Actual  Analysis
Planned       Treatment  Actual        Treatment     Visit
Treatment           (N)  Treatment           (N)       (N)
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                      Analysis
                                        Window
Analysis         Visit                   Visit  Analysis
Visit           Number  Visit              (N)  Window Visit
                                                     Baseline
Parameter                                            Record
Code       Parameter                                 Flag
                     Analysis  Analysis
Analaysis  Analysis     Date/  Relative  Parameter
     Date      Time      Time       Day  Category 1
                                                  Change
Parameter     Analysis  Analysis      Baseline      from
Category 2       Value  Value (C)        Value  Baseline
Percentage   Duration
    Change         of  Time-Dependent  Time-Dependent
      from  Treatment       covariate       covariate
  Baseline   in Weeks      for Week 1      for Week 4
                                              Criterion
                                              1
Time-Dependent  Time-Dependent                Evaluation
     covariate   covariate for  Analysis      Result
    for Week 8         Week 12  Criterion 1   Flag
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              Criterion                 Criterion
              2                         3
              Evaluation                Evaluation
Analysis      Result      Analysis      Result      Analysis
Criterion 2   Flag        Criterion 3   Flag        Criterion 4
Criterion
4
Evaluation  Analysis  Analysis  Analysis
Result      Record    Record    Record
Flag        Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1381-1002                    
13811002                                          
1381                  USA      1985-03-17          37  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               13811002/37/
                                                    M/W         
37/M             37/W/M      
Non-Hispanic or Latino                                      2
    79.0     182.0      23.9  2022-04-28  2022-04-28  2022-05-23
2022-11-06  2022-05-23  2022-07-13  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  23MAY2022
mg                       mg                                
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1985-03-17  Emilio Mantero Atineza         DISCONTINUED
13JUL2022  LOST TO FU                                        
LOST TO FU    DISCONTINUED                                      
LOST TO       LOST TO                                     
FOLLOW-UP     FOLLOW-UP                                   
N          N                                    
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Absence                              2  No                 2
No                 2                                      1381
       5         1  JZP150 0.3           5       182
                    mg                              
JZP150 0.3            1  JZP150 0.3            1         0
mg                       mg                               
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                                    
    22788     51180  1.9689E9         1  PGI         
POST-                3  MODERATE                        
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   24               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable                        Subject'
dose of      dose of                          s type
SSRI/SNRI  SSRI/SNRI  Subject's type        of visit
EDC          EDC (N)  of visit                   (N)      SITE
                                            Analysis
                                            Sequence
  site_n      trtn  trt            SITEIDN    Number
                Planned                   Actual  Analysis
Planned       Treatment  Actual        Treatment     Visit
Treatment           (N)  Treatment           (N)       (N)
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                      Analysis
                                        Window
Analysis         Visit                   Visit  Analysis
Visit           Number  Visit              (N)  Window Visit
                                                     Baseline
Parameter                                            Record
Code       Parameter                                 Flag
                     Analysis  Analysis
Analaysis  Analysis     Date/  Relative  Parameter
     Date      Time      Time       Day  Category 1
                                                  Change
Parameter     Analysis  Analysis      Baseline      from
Category 2       Value  Value (C)        Value  Baseline
Percentage   Duration
    Change         of  Time-Dependent  Time-Dependent
      from  Treatment       covariate       covariate
  Baseline   in Weeks      for Week 1      for Week 4
                                              Criterion
                                              1
Time-Dependent  Time-Dependent                Evaluation
     covariate   covariate for  Analysis      Result
    for Week 8         Week 12  Criterion 1   Flag
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              Criterion                 Criterion
              2                         3
              Evaluation                Evaluation
Analysis      Result      Analysis      Result      Analysis
Criterion 2   Flag        Criterion 3   Flag        Criterion 4
Criterion
4
Evaluation  Analysis  Analysis  Analysis
Result      Record    Record    Record
Flag        Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1399-1001                    
13991001                                          
1399                  USA      1960-09-28          61  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               13991001/61/
                                                    F/W         
61/F             61/W/F      
Hispanic or Latino                                          1
    86.4     157.5      34.8  2022-06-17  2022-06-17  2022-07-09
2022-07-12  2022-07-09  2022-09-22  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  09JUL2022
12JUL2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1960-09-28  Lissette Selem                 DISCONTINUED
22SEP2022  ENROLLED IN ERROR                                 
ENROLLED IN   DISCONTINUED                                      
ERROR                                                           
ENROLLED IN   LOW FAILURE                                 
ERROR         SCORE ON                                    
              PCL-5.                                      
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

N          Y          N                        2
Absence                              2  No                 2
No                 2                                      1399
       6         2  JZP150 4 mg          6       545
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22834     43980  1.9729E9        -1  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    1               0               1
             2               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1399-1002                    
13991002                                          
1399                  USA      1998-12-22          23  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               13991002/23/
                                                    F/W         
23/F             23/W/F      
Hispanic or Latino                                          1
    77.2     158.5      31.0  2022-07-13  2022-07-13  2022-07-29
2022-10-18  2022-07-29  2022-11-01  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  29JUL2022
mg                       mg                                
18OCT2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1998-12-22  Lissette Selem                 COMPLETED   
01NOV2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2  On-site                      1      1399
       6         1  JZP150 0.3           6       547
                    mg                              
JZP150 0.3            1  JZP150 0.3            1         0
mg                       mg                               
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22854     46620  1.9746E9        -1  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1399-1002                    
13991002                                          
1399                  USA      1998-12-22          23  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               13991002/23/
                                                    F/W         
23/F             23/W/F      
Hispanic or Latino                                          1
    77.2     158.5      31.0  2022-07-13  2022-07-13  2022-07-29
2022-10-18  2022-07-29  2022-11-01  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  29JUL2022
mg                       mg                                
18OCT2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1998-12-22  Lissette Selem                 COMPLETED   
01NOV2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2  On-site                      1      1399
       6         1  JZP150 0.3           6       551
                    mg                              
JZP150 0.3            1  JZP150 0.3            1        12
mg                       mg                               
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22936     37980  1.9817E9        82  PGI         
POST-                2  MILD                 4        -2
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
       -50         12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1399-1004                    
13991004                                          
1399                  USA      1998-03-03          24  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               13991004/24/
                                                    M/W         
24/M             24/W/M      
Hispanic or Latino                                          1
    92.5     180.3      28.4  2022-08-11  2022-08-11  2022-09-13
2022-11-06  2022-09-13  2022-11-06  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  13SEP2022
mg                       mg                                
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1998-03-03  Lissette Selem                 ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N                                    
Absence                              2  No                 2
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2                                      1399
       6         1  JZP150 0.3           6       364
                    mg                              
JZP150 0.3            1  JZP150 0.3            1         0
mg                       mg                               
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22900     36000  1.9786E9        -1  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    8               0               0
             0               1                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1399-1007                    
13991007                                          
1399                  USA      1958-04-26          64  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
BLACK OR AFRICAN AMERICAN                           13991007/64/
                                                    F/B         
64/F             64/B/F      
Non-Hispanic or Latino                                      2
    71.2     161.3      27.2  2022-09-07  2022-09-07  2022-10-01
2022-11-06  2022-10-01  2022-11-06  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  01OCT2022
mg                       mg                                
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1958-04-26  Lissette Selem                 ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          N                        2
Absence                              2  No                 2
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2                                      1399
       6         1  JZP150 0.3           6       363
                    mg                              
JZP150 0.3            1  JZP150 0.3            1         0
mg                       mg                               
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22918     40140  1.9802E9        -1  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    5               0               0
             1               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1399-1009                    
13991009                                          
1399                  USA      1957-11-22          64  YEARS
<=65 years                                                 1
>45 years                                                  2
M           1
BLACK OR AFRICAN AMERICAN                           13991009/64/
                                                    M/B         
64/M             64/B/M      
Non-Hispanic or Latino                                      2
    79.4     182.9      23.7  2022-09-20  2022-09-20  2022-10-19
2022-11-06  2022-10-19  2022-11-06  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  19OCT2022
mg                       mg                                
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1957-11-22  Lissette Selem                 ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N                                    
Absence                              2  No                 2
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2                                      1399
       6         1  JZP150 0.3           6       182
                    mg                              
JZP150 0.3            1  JZP150 0.3            1         0
mg                       mg                               
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22936     35700  1.9817E9        -1  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    3               0               1
             2               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1399-1010                    
13991010                                          
1399                  USA      1959-09-08          63  YEARS
<=65 years                                                 1
>45 years                                                  2
M           1
WHITE                                               13991010/63/
                                                    M/W         
63/M             63/W/M      
Non-Hispanic or Latino                                      2
    79.8     170.7      27.4  2022-09-22  2022-09-22  2022-10-15
2022-11-06  2022-10-15  2022-11-06  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  15OCT2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1959-09-08  Lissette Selem                 ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N                                    
Absence                              2  No                 2
No                 2                                      1399
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       6         2  JZP150 4 mg          6       182
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22932     41520  1.9814E9        -1  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    3               0               1
             2               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable                        Subject'
dose of      dose of                          s type
SSRI/SNRI  SSRI/SNRI  Subject's type        of visit
EDC          EDC (N)  of visit                   (N)      SITE
                                            Analysis
                                            Sequence
  site_n      trtn  trt            SITEIDN    Number
                Planned                   Actual  Analysis
Planned       Treatment  Actual        Treatment     Visit
Treatment           (N)  Treatment           (N)       (N)
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                      Analysis
                                        Window
Analysis         Visit                   Visit  Analysis
Visit           Number  Visit              (N)  Window Visit
                                                     Baseline
Parameter                                            Record
Code       Parameter                                 Flag
                     Analysis  Analysis
Analaysis  Analysis     Date/  Relative  Parameter
     Date      Time      Time       Day  Category 1
                                                  Change
Parameter     Analysis  Analysis      Baseline      from
Category 2       Value  Value (C)        Value  Baseline
Percentage   Duration
    Change         of  Time-Dependent  Time-Dependent
      from  Treatment       covariate       covariate
  Baseline   in Weeks      for Week 1      for Week 4
                                              Criterion
                                              1
Time-Dependent  Time-Dependent                Evaluation
     covariate   covariate for  Analysis      Result
    for Week 8         Week 12  Criterion 1   Flag
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              Criterion                 Criterion
              2                         3
              Evaluation                Evaluation
Analysis      Result      Analysis      Result      Analysis
Criterion 2   Flag        Criterion 3   Flag        Criterion 4
Criterion
4
Evaluation  Analysis  Analysis  Analysis
Result      Record    Record    Record
Flag        Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1659-1001                    
16591001                                          
1659                  USA      1965-11-20          56  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               16591001/56/
                                                    F/W         
56/F             56/W/F      
Non-Hispanic or Latino                                      2
    80.0     165.1      29.1  2022-01-20  2022-01-20  2022-02-09
2022-02-27  2022-02-09  2022-03-15  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  09FEB2022
mg                       mg                                
27FEB2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1965-11-20  Walter Duffy                   DISCONTINUED
15MAR2022  ADVERSE EVENT                                     
AE001-        DISCONTINUED                                      
BRONCHITIS-                                                     
14 FEB 2022                                                     
ADVERSE       AE001-                                      
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

EVENT         BRONCHITIS-                                 
              14 FEB 2022                                 
N          N          N                        2
Absence                              2  No                 2
No                 2                                      1659
       7         1  JZP150 0.3           7       365
                    mg                              
JZP150 0.3            1  JZP150 0.3            1         0
mg                       mg                               
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22684     40380  1.9599E9        -1  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    3               0               1
             2               2                          
                                                                
            Y                   Y       
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1659-1003                    
16591003                                          
1659                  USA      1964-12-29          57  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               16591003/57/
                                                    F/W         
57/F             57/W/F      
Non-Hispanic or Latino                                      2
    72.3     162.5      27.2  2022-01-26  2022-01-26  2022-02-16
2022-03-22  2022-02-16  2022-04-07  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  16FEB2022
22MAR2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1964-12-29  Walter Duffy                   DISCONTINUED
07APR2022  ADVERSE EVENT                                     
AE001-        DISCONTINUED                                      
INSOMNIA-17                                                     
FEB 2022                                                        
ADVERSE       AE001-                                      
EVENT         INSOMNIA-17                                 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              FEB 2022                                    
N          N          N                        2
Absence                              2  No                 2
No                 2                                      1659
       7         2  JZP150 4 mg          7       544
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22691     51780  1.9606E9        -1  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    5               0               0
             1               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1659-1006                    
16591006                                          
1659                  USA      1988-04-29          33  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               16591006/33/
                                                    F/W         
33/F             33/W/F      
Non-Hispanic or Latino                                      2
    63.9     165.1      24.3  2022-03-08  2022-03-08  2022-03-22
2022-06-13  2022-03-22  2022-06-29  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  22MAR2022
13JUN2022  Y           Y                                 
Y           Y           Y         Y         Y          Y        
1988-04-29  Walter Duffy                   COMPLETED   
29JUN2022                                                    
              COMPLETED                                         
                                                          
N          N          N                        2
Absence                              2  No                 2
No                 2  On-site                      1      1659
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       7         2  JZP150 4 mg          7       547
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22725     59040  1.9635E9        -1  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1659-1006                    
16591006                                          
1659                  USA      1988-04-29          33  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               16591006/33/
                                                    F/W         
33/F             33/W/F      
Non-Hispanic or Latino                                      2
    63.9     165.1      24.3  2022-03-08  2022-03-08  2022-03-22
2022-06-13  2022-03-22  2022-06-29  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  22MAR2022
13JUN2022  Y           Y                                 
Y           Y           Y         Y         Y          Y        
1988-04-29  Walter Duffy                   COMPLETED   
29JUN2022                                                    
              COMPLETED                                         
                                                          
N          N          N                        2
Absence                              2  No                 2
No                 2  On-site                      1      1659
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       7         2  JZP150 4 mg          7       551
JZP150 4 mg           2  JZP150 4 mg           2        12
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22809     39480  1.9707E9        84  PGI         
POST-                3  MODERATE             3         0
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
         0         12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable                        Subject'
dose of      dose of                          s type
SSRI/SNRI  SSRI/SNRI  Subject's type        of visit
EDC          EDC (N)  of visit                   (N)      SITE
                                            Analysis
                                            Sequence
  site_n      trtn  trt            SITEIDN    Number
                Planned                   Actual  Analysis
Planned       Treatment  Actual        Treatment     Visit
Treatment           (N)  Treatment           (N)       (N)
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                      Analysis
                                        Window
Analysis         Visit                   Visit  Analysis
Visit           Number  Visit              (N)  Window Visit
                                                     Baseline
Parameter                                            Record
Code       Parameter                                 Flag
                     Analysis  Analysis
Analaysis  Analysis     Date/  Relative  Parameter
     Date      Time      Time       Day  Category 1
                                                  Change
Parameter     Analysis  Analysis      Baseline      from
Category 2       Value  Value (C)        Value  Baseline
Percentage   Duration
    Change         of  Time-Dependent  Time-Dependent
      from  Treatment       covariate       covariate
  Baseline   in Weeks      for Week 1      for Week 4
                                              Criterion
                                              1
Time-Dependent  Time-Dependent                Evaluation
     covariate   covariate for  Analysis      Result
    for Week 8         Week 12  Criterion 1   Flag
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              Criterion                 Criterion
              2                         3
              Evaluation                Evaluation
Analysis      Result      Analysis      Result      Analysis
Criterion 2   Flag        Criterion 3   Flag        Criterion 4
Criterion
4
Evaluation  Analysis  Analysis  Analysis
Result      Record    Record    Record
Flag        Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1002                    
17601002                                          
1760                  USA      1993-02-15          28  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
BLACK OR AFRICAN AMERICAN                           17601002/28/
                                                    F/B         
28/F             28/B/F      
Non-Hispanic or Latino                                      2
   105.2     175.3      34.6  2022-01-07  2022-01-07  2022-01-22
2022-04-15  2022-01-22  2022-07-07  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  22JAN2022
15APR2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1993-02-15  Donald J. Garcia               DISCONTINUED
07JUL2022  LOST TO FU                                        
LOST TO FU    COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2  On-site                      1      1760
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       8         2  JZP150 4 mg          8       545
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22666     46020  1.9584E9        -1  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1002                    
17601002                                          
1760                  USA      1993-02-15          28  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
BLACK OR AFRICAN AMERICAN                           17601002/28/
                                                    F/B         
28/F             28/B/F      
Non-Hispanic or Latino                                      2
   105.2     175.3      34.6  2022-01-07  2022-01-07  2022-01-22
2022-04-15  2022-01-22  2022-07-07  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  22JAN2022
15APR2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1993-02-15  Donald J. Garcia               DISCONTINUED
07JUL2022  LOST TO FU                                        
LOST TO FU    COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2  On-site                      1      1760
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       8         2  JZP150 4 mg          8       549
JZP150 4 mg           2  JZP150 4 mg           2        12
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22750     44520  1.9656E9        84  PGI         
POST-                2  MILD                 3        -1
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
  -33.3333         12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1003                    
17601003                                          
1760                  USA      1989-09-22          32  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               17601003/32/
                                                    M/W         
32/M             32/W/M      
Non-Hispanic or Latino                                      2
   111.6     179.1      34.5  2022-01-12  2022-01-12  2022-01-22
2022-04-19  2022-01-22  2022-05-04  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  22JAN2022
19APR2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1989-09-22  Donald J. Garcia               COMPLETED   
04MAY2022                                                    
              COMPLETED                                         
                                                          
N          N                                    
Presence                             1  Yes                1
Yes                1  On-site                      1      1760
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       8         2  JZP150 4 mg          8       547
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22666     39300  1.9584E9        -1  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   13               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1003                    
17601003                                          
1760                  USA      1989-09-22          32  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               17601003/32/
                                                    M/W         
32/M             32/W/M      
Non-Hispanic or Latino                                      2
   111.6     179.1      34.5  2022-01-12  2022-01-12  2022-01-22
2022-04-19  2022-01-22  2022-05-04  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  22JAN2022
19APR2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1989-09-22  Donald J. Garcia               COMPLETED   
04MAY2022                                                    
              COMPLETED                                         
                                                          
N          N                                    
Presence                             1  Yes                1
Yes                1  On-site                      1      1760
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       8         2  JZP150 4 mg          8       551
JZP150 4 mg           2  JZP150 4 mg           2        12
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22754     41460   1.966E9        88  PGI         
POST-                3  MODERATE             4        -1
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
       -25         13               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1005                    
17601005                                          
1760                  USA      1972-12-02          49  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               17601005/49/
                                                    F/W         
49/F             49/W/F      
Hispanic or Latino                                          1
    65.0     162.1      24.3  2022-02-07  2022-02-07  2022-03-01
2022-05-24  2022-03-01  2022-06-14  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  01MAR2022
mg                       mg                                
24MAY2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1972-12-02  Donald J. Garcia               COMPLETED   
14JUN2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2  On-site                      1      1760
       8         1  JZP150 0.3           8       545
                    mg                              
JZP150 0.3            1  JZP150 0.3            1         0
mg                       mg                               
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22704     38220  1.9617E9        -1  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1005                    
17601005                                          
1760                  USA      1972-12-02          49  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               17601005/49/
                                                    F/W         
49/F             49/W/F      
Hispanic or Latino                                          1
    65.0     162.1      24.3  2022-02-07  2022-02-07  2022-03-01
2022-05-24  2022-03-01  2022-06-14  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  01MAR2022
mg                       mg                                
24MAY2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1972-12-02  Donald J. Garcia               COMPLETED   
14JUN2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2  On-site                      1      1760
       8         1  JZP150 0.3           8       549
                    mg                              
JZP150 0.3            1  JZP150 0.3            1        12
mg                       mg                               
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22789     60660   1.969E9        85  PGI         
POST-                3  MODERATE             4        -1
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
       -25         12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1007                    
17601007                                          
1760                  USA      1961-01-02          61  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               17601007/61/
                                                    F/W         
61/F             61/W/F      
Non-Hispanic or Latino                                      2
    57.5     160.0      22.7  2022-03-11  2022-03-11  2022-03-25
2022-06-15  2022-03-25  2022-06-29  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  25MAR2022
15JUN2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1961-01-02  Donald J. Garcia               COMPLETED   
29JUN2022                                                    
              COMPLETED                                         
                                                          
N          N                                    
Absence                              2  No                 2
No                 2  On-site                      1      1760
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       8         3  Placebo              8       547
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22728     32940  1.9637E9        -1  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1007                    
17601007                                          
1760                  USA      1961-01-02          61  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               17601007/61/
                                                    F/W         
61/F             61/W/F      
Non-Hispanic or Latino                                      2
    57.5     160.0      22.7  2022-03-11  2022-03-11  2022-03-25
2022-06-15  2022-03-25  2022-06-29  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  25MAR2022
15JUN2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1961-01-02  Donald J. Garcia               COMPLETED   
29JUN2022                                                    
              COMPLETED                                         
                                                          
N          N                                    
Absence                              2  No                 2
No                 2  On-site                      1      1760
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       8         3  Placebo              8       551
Placebo               3  Placebo               3        12
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22811     37140  1.9709E9        83  PGI         
POST-                1  NONE                 3        -2
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
  -66.6667         12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1012                    
17601012                                          
1760                  USA      1977-04-28          45  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17601012/45/
                                                    F/W         
45/F             45/W/F      
Non-Hispanic or Latino                                      2
    90.2     164.3      34.3  2022-05-05  2022-05-05  2022-05-27
2022-08-18  2022-05-27  2022-09-01  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  27MAY2022
18AUG2022  Y           Y                                 
Y           Y           Y         Y         Y          Y        
1977-04-28  Donald J. Garcia               COMPLETED   
01SEP2022                                                    
              COMPLETED                                         
                                                          
N          N          N                        2
Absence                              2  No                 2
No                 2  On-site                      1      1760
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       8         2  JZP150 4 mg          8       547
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22791     36060  1.9692E9        -1  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1012                    
17601012                                          
1760                  USA      1977-04-28          45  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17601012/45/
                                                    F/W         
45/F             45/W/F      
Non-Hispanic or Latino                                      2
    90.2     164.3      34.3  2022-05-05  2022-05-05  2022-05-27
2022-08-18  2022-05-27  2022-09-01  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  27MAY2022
18AUG2022  Y           Y                                 
Y           Y           Y         Y         Y          Y        
1977-04-28  Donald J. Garcia               COMPLETED   
01SEP2022                                                    
              COMPLETED                                         
                                                          
N          N          N                        2
Absence                              2  No                 2
No                 2  On-site                      1      1760
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       8         2  JZP150 4 mg          8       551
JZP150 4 mg           2  JZP150 4 mg           2        12
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22875     36240  1.9764E9        84  PGI         
POST-                1  NONE                 4        -3
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
       -75         12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1014                    
17601014                                          
1760                  USA      1976-07-31          45  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17601014/45/
                                                    F/W         
45/F             45/W/F      
Hispanic or Latino                                          1
    68.7     162.6      25.8  2022-05-19  2022-05-19  2022-06-08
2022-09-01  2022-06-08  2022-09-23  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  08JUN2022
mg                       mg                                
01SEP2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1976-07-31  Donald J. Garcia               COMPLETED   
23SEP2022                                                    
              COMPLETED                                         
                                                          
N          N                                    
Absence                              2  No                 2
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2  On-site                      1      1760
       8         1  JZP150 0.3           8       547
                    mg                              
JZP150 0.3            1  JZP150 0.3            1         0
mg                       mg                               
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22803     54000  1.9702E9        -1  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1014                    
17601014                                          
1760                  USA      1976-07-31          45  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17601014/45/
                                                    F/W         
45/F             45/W/F      
Hispanic or Latino                                          1
    68.7     162.6      25.8  2022-05-19  2022-05-19  2022-06-08
2022-09-01  2022-06-08  2022-09-23  Dummy Treatment A
A                     Dummy Treatment A  A                   
JZP150 0.3            1  JZP150 0.3            1  08JUN2022
mg                       mg                                
01SEP2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1976-07-31  Donald J. Garcia               COMPLETED   
23SEP2022                                                    
              COMPLETED                                         
                                                          
N          N                                    
Absence                              2  No                 2
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2  On-site                      1      1760
       8         1  JZP150 0.3           8       551
                    mg                              
JZP150 0.3            1  JZP150 0.3            1        12
mg                       mg                               
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22889     37740  1.9776E9        86  PGI         
POST-                2  MILD                 4        -2
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
       -50         12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1022                    
17601022                                          
1760                  USA      1985-04-10          37  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
MULTIPLE                                            17601022/37/
                                                    F/MU: A, W  
37/F             37/MU: A,   
                 W/F         
Non-Hispanic or Latino                                      2
    95.3     165.9      34.7  2022-08-12  2022-08-12  2022-09-09
2022-11-06  2022-09-09  2022-11-06  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  09SEP2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1985-04-10  Donald J. Garcia               ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

No                 2                                      1760
       8         2  JZP150 4 mg          8       364
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                                    
    22897     51420  1.9784E9         1  PGI         
POST-                3  MODERATE                        
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    8               0               0
             0               1                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1025                    
17601025                                          
1760                  USA      1998-02-03          24  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17601025/24/
                                                    F/W         
24/F             24/W/F      
Non-Hispanic or Latino                                      2
    74.2     160.8      28.4  2022-09-01  2022-09-01  2022-09-14
2022-10-22  2022-09-14  2022-10-22  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  14SEP2022
22OCT2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1998-02-03  Donald J. Garcia               ONGOING     
                                                             
              DISCONTINUED                                      
WITHDRAWAL    WITHDRAWAL                                  
OF CONSENT    OF CONSENT                                  
BY STUDY      BY STUDY                                    
PARTICIPANT   PARTICIPANT                                 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

N          N          Y                        1
Presence                             1  Yes                1
Yes                1                                      1760
       8         2  JZP150 4 mg          8       544
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22901     43020  1.9787E9        -1  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    6               0               0
             1               1                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1760-1025                    
17601025                                          
1760                  USA      1998-02-03          24  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17601025/24/
                                                    F/W         
24/F             24/W/F      
Non-Hispanic or Latino                                      2
    74.2     160.8      28.4  2022-09-01  2022-09-01  2022-09-14
2022-10-22  2022-09-14  2022-10-22  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  14SEP2022
22OCT2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1998-02-03  Donald J. Garcia               ONGOING     
                                                             
              DISCONTINUED                                      
WITHDRAWAL    WITHDRAWAL                                  
OF CONSENT    OF CONSENT                                  
BY STUDY      BY STUDY                                    
PARTICIPANT   PARTICIPANT                                 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

N          N          Y                        1
Presence                             1  Yes                1
Yes                1                                      1760
       8         2  JZP150 4 mg          8       547
JZP150 4 mg           2  JZP150 4 mg           2        12
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22943     35100  1.9823E9        42  PGI         
POST-                2  MILD                 3        -1
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
  -33.3333          6               0               0
             1               1                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable                        Subject'
dose of      dose of                          s type
SSRI/SNRI  SSRI/SNRI  Subject's type        of visit
EDC          EDC (N)  of visit                   (N)      SITE
                                            Analysis
                                            Sequence
  site_n      trtn  trt            SITEIDN    Number
                Planned                   Actual  Analysis
Planned       Treatment  Actual        Treatment     Visit
Treatment           (N)  Treatment           (N)       (N)
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                      Analysis
                                        Window
Analysis         Visit                   Visit  Analysis
Visit           Number  Visit              (N)  Window Visit
                                                     Baseline
Parameter                                            Record
Code       Parameter                                 Flag
                     Analysis  Analysis
Analaysis  Analysis     Date/  Relative  Parameter
     Date      Time      Time       Day  Category 1
                                                  Change
Parameter     Analysis  Analysis      Baseline      from
Category 2       Value  Value (C)        Value  Baseline
Percentage   Duration
    Change         of  Time-Dependent  Time-Dependent
      from  Treatment       covariate       covariate
  Baseline   in Weeks      for Week 1      for Week 4
                                              Criterion
                                              1
Time-Dependent  Time-Dependent                Evaluation
     covariate   covariate for  Analysis      Result
    for Week 8         Week 12  Criterion 1   Flag
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              Criterion                 Criterion
              2                         3
              Evaluation                Evaluation
Analysis      Result      Analysis      Result      Analysis
Criterion 2   Flag        Criterion 3   Flag        Criterion 4
Criterion
4
Evaluation  Analysis  Analysis  Analysis
Result      Record    Record    Record
Flag        Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1766-1002                    
17661002                                          
1766                  USA      1971-01-01          51  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               17661002/51/
                                                    F/W         
51/F             51/W/F      
Non-Hispanic or Latino                                      2
   108.1     177.8      34.4  2022-06-23  2022-06-23  2022-07-15
2022-10-06  2022-07-15  2022-10-20  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  15JUL2022
06OCT2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1971-01-01  Benny L. Barnhart, MD          COMPLETED   
20OCT2022                                                    
              COMPLETED                                         
                                                          
N          N          N                        2
Absence                              2  No                 2
No                 2  On-site                      1      1766
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       9         2  JZP150 4 mg          9       366
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22840     39540  1.9734E9        -1  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1766-1002                    
17661002                                          
1766                  USA      1971-01-01          51  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               17661002/51/
                                                    F/W         
51/F             51/W/F      
Non-Hispanic or Latino                                      2
   108.1     177.8      34.4  2022-06-23  2022-06-23  2022-07-15
2022-10-06  2022-07-15  2022-10-20  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  15JUL2022
06OCT2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1971-01-01  Benny L. Barnhart, MD          COMPLETED   
20OCT2022                                                    
              COMPLETED                                         
                                                          
N          N          N                        2
Absence                              2  No                 2
No                 2  On-site                      1      1766
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       9         2  JZP150 4 mg          9       370
JZP150 4 mg           2  JZP150 4 mg           2        12
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22924     34380  1.9807E9        84  PGI         
POST-                3  MODERATE             4        -1
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
       -25         12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1766-1004                    
17661004                                          
1766                  USA      1987-04-03          35  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17661004/35/
                                                    F/W         
35/F             35/W/F      
Non-Hispanic or Latino                                      2
    85.6     167.6      30.0  2022-07-07  2022-07-07  2022-07-22
2022-10-13  2022-07-22  2022-10-27  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  22JUL2022
13OCT2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1987-04-03  Benny L. Barnhart, MD          COMPLETED   
27OCT2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2  On-site                      1      1766
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       9         3  Placebo              9       729
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22847     52560   1.974E9        -1  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1766-1004                    
17661004                                          
1766                  USA      1987-04-03          35  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17661004/35/
                                                    F/W         
35/F             35/W/F      
Non-Hispanic or Latino                                      2
    85.6     167.6      30.0  2022-07-07  2022-07-07  2022-07-22
2022-10-13  2022-07-22  2022-10-27  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  22JUL2022
13OCT2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1987-04-03  Benny L. Barnhart, MD          COMPLETED   
27OCT2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2  On-site                      1      1766
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       9         3  Placebo              9       733
Placebo               3  Placebo               3        12
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22931     57120  1.9813E9        84  PGI         
POST-                1  NONE                 4        -3
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
       -75         12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1766-1006                    
17661006                                          
1766                  USA      1986-07-22          36  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               17661006/36/
                                                    F/W         
36/F             36/W/F      
Non-Hispanic or Latino                                      2
    79.5     160.0      30.6  2022-09-22  2022-09-22  2022-10-14
2022-11-06  2022-10-14  2022-11-06  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  14OCT2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1986-07-22  Benny L. Barnhart, MD          ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2                                      1766
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

       9         2  JZP150 4 mg          9       182
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22931     53640  1.9813E9        -1  PGI         
POST-                2  MILD                 2          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    3               0               1
             2               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable                        Subject'
dose of      dose of                          s type
SSRI/SNRI  SSRI/SNRI  Subject's type        of visit
EDC          EDC (N)  of visit                   (N)      SITE
                                            Analysis
                                            Sequence
  site_n      trtn  trt            SITEIDN    Number
                Planned                   Actual  Analysis
Planned       Treatment  Actual        Treatment     Visit
Treatment           (N)  Treatment           (N)       (N)
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                      Analysis
                                        Window
Analysis         Visit                   Visit  Analysis
Visit           Number  Visit              (N)  Window Visit
                                                     Baseline
Parameter                                            Record
Code       Parameter                                 Flag
                     Analysis  Analysis
Analaysis  Analysis     Date/  Relative  Parameter
     Date      Time      Time       Day  Category 1
                                                  Change
Parameter     Analysis  Analysis      Baseline      from
Category 2       Value  Value (C)        Value  Baseline
Percentage   Duration
    Change         of  Time-Dependent  Time-Dependent
      from  Treatment       covariate       covariate
  Baseline   in Weeks      for Week 1      for Week 4
                                              Criterion
                                              1
Time-Dependent  Time-Dependent                Evaluation
     covariate   covariate for  Analysis      Result
    for Week 8         Week 12  Criterion 1   Flag
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              Criterion                 Criterion
              2                         3
              Evaluation                Evaluation
Analysis      Result      Analysis      Result      Analysis
Criterion 2   Flag        Criterion 3   Flag        Criterion 4
Criterion
4
Evaluation  Analysis  Analysis  Analysis
Result      Record    Record    Record
Flag        Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1768-1001                    
17681001                                          
1768                  USA      1973-05-07          49  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
BLACK OR AFRICAN AMERICAN                           17681001/49/
                                                    F/B         
49/F             49/B/F      
Non-Hispanic or Latino                                      2
   108.9     180.0      33.6  2022-07-29  2022-07-29  2022-08-25
2022-11-06  2022-08-25  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  25AUG2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1973-05-07  Scott Bartley                  ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          N                        2
Presence                             1  Yes                1
Yes                1                                      1768
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      10         3  Placebo             10       364
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                                    
    22882     40020   1.977E9         1  PGI         
POST-                4  SEVERE                          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   11               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable                        Subject'
dose of      dose of                          s type
SSRI/SNRI  SSRI/SNRI  Subject's type        of visit
EDC          EDC (N)  of visit                   (N)      SITE
                                            Analysis
                                            Sequence
  site_n      trtn  trt            SITEIDN    Number
                Planned                   Actual  Analysis
Planned       Treatment  Actual        Treatment     Visit
Treatment           (N)  Treatment           (N)       (N)
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                      Analysis
                                        Window
Analysis         Visit                   Visit  Analysis
Visit           Number  Visit              (N)  Window Visit
                                                     Baseline
Parameter                                            Record
Code       Parameter                                 Flag
                     Analysis  Analysis
Analaysis  Analysis     Date/  Relative  Parameter
     Date      Time      Time       Day  Category 1
                                                  Change
Parameter     Analysis  Analysis      Baseline      from
Category 2       Value  Value (C)        Value  Baseline
Percentage   Duration
    Change         of  Time-Dependent  Time-Dependent
      from  Treatment       covariate       covariate
  Baseline   in Weeks      for Week 1      for Week 4
                                              Criterion
                                              1
Time-Dependent  Time-Dependent                Evaluation
     covariate   covariate for  Analysis      Result
    for Week 8         Week 12  Criterion 1   Flag
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              Criterion                 Criterion
              2                         3
              Evaluation                Evaluation
Analysis      Result      Analysis      Result      Analysis
Criterion 2   Flag        Criterion 3   Flag        Criterion 4
Criterion
4
Evaluation  Analysis  Analysis  Analysis
Result      Record    Record    Record
Flag        Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1861-1001                    
18611001                                          
1861                  USA      1986-10-04          35  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               18611001/35/
                                                    F/W         
35/F             35/W/F      
Hispanic or Latino                                          1
    95.0     166.5      34.3  2022-08-15  2022-08-15  2022-08-31
2022-11-06  2022-08-31  2022-11-06  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  31AUG2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1986-10-04  Jelena Kunovac                 ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2                                      1861
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      11         2  JZP150 4 mg         11       363
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                                    
    22888     39540  1.9776E9         1  PGI         
POST-                4  SEVERE                          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   10               0               0
             0               1                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable                        Subject'
dose of      dose of                          s type
SSRI/SNRI  SSRI/SNRI  Subject's type        of visit
EDC          EDC (N)  of visit                   (N)      SITE
                                            Analysis
                                            Sequence
  site_n      trtn  trt            SITEIDN    Number
                Planned                   Actual  Analysis
Planned       Treatment  Actual        Treatment     Visit
Treatment           (N)  Treatment           (N)       (N)
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                      Analysis
                                        Window
Analysis         Visit                   Visit  Analysis
Visit           Number  Visit              (N)  Window Visit
                                                     Baseline
Parameter                                            Record
Code       Parameter                                 Flag
                     Analysis  Analysis
Analaysis  Analysis     Date/  Relative  Parameter
     Date      Time      Time       Day  Category 1
                                                  Change
Parameter     Analysis  Analysis      Baseline      from
Category 2       Value  Value (C)        Value  Baseline
Percentage   Duration
    Change         of  Time-Dependent  Time-Dependent
      from  Treatment       covariate       covariate
  Baseline   in Weeks      for Week 1      for Week 4
                                              Criterion
                                              1
Time-Dependent  Time-Dependent                Evaluation
     covariate   covariate for  Analysis      Result
    for Week 8         Week 12  Criterion 1   Flag
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              Criterion                 Criterion
              2                         3
              Evaluation                Evaluation
Analysis      Result      Analysis      Result      Analysis
Criterion 2   Flag        Criterion 3   Flag        Criterion 4
Criterion
4
Evaluation  Analysis  Analysis  Analysis
Result      Record    Record    Record
Flag        Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1969-1001                    
19691001                                          
1969                  USA      1994-06-30          28  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               19691001/28/
                                                    F/W         
28/F             28/W/F      
Hispanic or Latino                                          1
    71.5     161.1      27.8  2022-09-13  2022-09-13  2022-10-12
2022-11-06  2022-10-12  2022-11-06  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  12OCT2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1994-06-30  Tony Ortiz, PhD                ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2                                      1969
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      12         2  JZP150 4 mg         12       182
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22929     47220  1.9811E9        -1  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    4               0               0
             1               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable                        Subject'
dose of      dose of                          s type
SSRI/SNRI  SSRI/SNRI  Subject's type        of visit
EDC          EDC (N)  of visit                   (N)      SITE
                                            Analysis
                                            Sequence
  site_n      trtn  trt            SITEIDN    Number
                Planned                   Actual  Analysis
Planned       Treatment  Actual        Treatment     Visit
Treatment           (N)  Treatment           (N)       (N)
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                      Analysis
                                        Window
Analysis         Visit                   Visit  Analysis
Visit           Number  Visit              (N)  Window Visit
                                                     Baseline
Parameter                                            Record
Code       Parameter                                 Flag
                     Analysis  Analysis
Analaysis  Analysis     Date/  Relative  Parameter
     Date      Time      Time       Day  Category 1
                                                  Change
Parameter     Analysis  Analysis      Baseline      from
Category 2       Value  Value (C)        Value  Baseline
Percentage   Duration
    Change         of  Time-Dependent  Time-Dependent
      from  Treatment       covariate       covariate
  Baseline   in Weeks      for Week 1      for Week 4
                                              Criterion
                                              1
Time-Dependent  Time-Dependent                Evaluation
     covariate   covariate for  Analysis      Result
    for Week 8         Week 12  Criterion 1   Flag
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              Criterion                 Criterion
              2                         3
              Evaluation                Evaluation
Analysis      Result      Analysis      Result      Analysis
Criterion 2   Flag        Criterion 3   Flag        Criterion 4
Criterion
4
Evaluation  Analysis  Analysis  Analysis
Result      Record    Record    Record
Flag        Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1973-1001                    
19731001                                          
1973                  USA      1992-06-30          29  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
ASIAN                                               19731001/29/
                                                    F/A         
29/F             29/A/F      
Non-Hispanic or Latino                                      2
    68.0     155.0      27.6  2022-03-07  2022-03-07  2022-03-30
2022-06-14  2022-03-30  2022-06-28  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  30MAR2022
14JUN2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1992-06-30  Sherry Soefje                  COMPLETED   
28JUN2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2  On-site                      1      1973
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      13         2  JZP150 4 mg         13       547
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22733     39660  1.9642E9        -1  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   11               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1973-1001                    
19731001                                          
1973                  USA      1992-06-30          29  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
ASIAN                                               19731001/29/
                                                    F/A         
29/F             29/A/F      
Non-Hispanic or Latino                                      2
    68.0     155.0      27.6  2022-03-07  2022-03-07  2022-03-30
2022-06-14  2022-03-30  2022-06-28  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  30MAR2022
14JUN2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1992-06-30  Sherry Soefje                  COMPLETED   
28JUN2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2  On-site                      1      1973
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      13         2  JZP150 4 mg         13       551
JZP150 4 mg           2  JZP150 4 mg           2        12
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22810     40500  1.9708E9        77  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   11               0               0
             0               0                          
                                                                
                                Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1973-1002                    
19731002                                          
1973                  USA      2000-04-23          21  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               19731002/21/
                                                    F/W         
21/F             21/W/F      
Non-Hispanic or Latino                                      2
    66.5     169.0      23.4  2022-04-18  2022-04-18  2022-05-06
2022-07-26  2022-05-06  2022-08-15  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  06MAY2022
26JUL2022  Y           Y                                 
Y           Y           Y         Y         Y          Y        
2000-04-23  Sherry Soefje                  COMPLETED   
15AUG2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Presence                             1  Yes                1
Yes                1  On-site                      1      1973
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      13         3  Placebo             13       547
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22768     40140  1.9672E9        -3  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1973-1002                    
19731002                                          
1973                  USA      2000-04-23          21  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               19731002/21/
                                                    F/W         
21/F             21/W/F      
Non-Hispanic or Latino                                      2
    66.5     169.0      23.4  2022-04-18  2022-04-18  2022-05-06
2022-07-26  2022-05-06  2022-08-15  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  06MAY2022
26JUL2022  Y           Y                                 
Y           Y           Y         Y         Y          Y        
2000-04-23  Sherry Soefje                  COMPLETED   
15AUG2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Presence                             1  Yes                1
Yes                1  On-site                      1      1973
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      13         3  Placebo             13       551
Placebo               3  Placebo               3        12
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22852     59400  1.9745E9        82  PGI         
POST-                3  MODERATE             4        -1
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
       -25         12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1973-1004                    
19731004                                          
1973                  USA      1991-01-22          31  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               19731004/31/
                                                    M/W         
31/M             31/W/M      
Non-Hispanic or Latino                                      2
    78.3     174.0      25.9  2022-05-03  2022-05-03  2022-05-18
2022-05-25  2022-05-18  2022-06-08  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  18MAY2022
25MAY2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1991-01-22  Sherry Soefje                  DISCONTINUED
08JUN2022  ENROLLED IN ERROR                                 
THE PATIENT   DISCONTINUED                                      
WAS ENROLLED                                                    
IN ERROR AND                                                    
REFUSED TO                                                      
COMPLETE                                                        
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

FOLLOW-UP                                                       
VISITS AFTER                                                    
WITHDRAWING                                                     
CONSENT.                                                        
ENROLLED IN   THE PATIENT                                 
ERROR         WAS ENROLLED                                
              IN ERROR AND                                
              REFUSED TO                                  
              COMPLETE                                    
              FOLLOW-UP                                   
              VISITS AFTER                                
              WITHDRAWING                                 
              CONSENT.                                    
N          N                                    
Absence                              2  No                 2
No                 2                                      1973
      13         2  JZP150 4 mg         13       182
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22782     52740  1.9684E9        -1  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    1               0               1
             2               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1973-1006                    
19731006                                          
1973                  USA      1994-09-02          27  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               19731006/27/
                                                    F/W         
27/F             27/W/F      
Non-Hispanic or Latino                                      2
    57.4     162.0      22.0  2022-07-14  2022-07-14  2022-08-16
2022-11-06  2022-08-16  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  16AUG2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1994-09-02  Sherry Soefje                  ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2                                      1973
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      13         3  Placebo             13       545
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22866     56340  1.9757E9        -7  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1973-1006                    
19731006                                          
1973                  USA      1994-09-02          27  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               19731006/27/
                                                    F/W         
27/F             27/W/F      
Non-Hispanic or Latino                                      2
    57.4     162.0      22.0  2022-07-14  2022-07-14  2022-08-16
2022-11-06  2022-08-16  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  16AUG2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1994-09-02  Sherry Soefje                  ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2                                      1973
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      13         3  Placebo             13       549
Placebo               3  Placebo               3        12
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22952     53520  1.9831E9        80  PGI         
POST-                2  MILD                 3        -1
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
  -33.3333         12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1973-1007                    
19731007                                          
1973                  USA      1975-09-01          46  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               19731007/46/
                                                    F/W         
46/F             46/W/F      
Hispanic or Latino                                          1
    81.0     162.0      30.9  2022-08-16  2022-08-16  2022-08-30
2022-11-06  2022-08-30  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  30AUG2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          Y        
1975-09-01  Sherry Soefje                  ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Presence                             1  Yes                1
Yes                1                                      1973
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      13         3  Placebo             13       364
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                                    
    22887     47160  1.9775E9         1  PGI         
POST-                4  SEVERE                          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   10               0               0
             0               1                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable                        Subject'
dose of      dose of                          s type
SSRI/SNRI  SSRI/SNRI  Subject's type        of visit
EDC          EDC (N)  of visit                   (N)      SITE
                                            Analysis
                                            Sequence
  site_n      trtn  trt            SITEIDN    Number
                Planned                   Actual  Analysis
Planned       Treatment  Actual        Treatment     Visit
Treatment           (N)  Treatment           (N)       (N)
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                      Analysis
                                        Window
Analysis         Visit                   Visit  Analysis
Visit           Number  Visit              (N)  Window Visit
                                                     Baseline
Parameter                                            Record
Code       Parameter                                 Flag
                     Analysis  Analysis
Analaysis  Analysis     Date/  Relative  Parameter
     Date      Time      Time       Day  Category 1
                                                  Change
Parameter     Analysis  Analysis      Baseline      from
Category 2       Value  Value (C)        Value  Baseline
Percentage   Duration
    Change         of  Time-Dependent  Time-Dependent
      from  Treatment       covariate       covariate
  Baseline   in Weeks      for Week 1      for Week 4
                                              Criterion
                                              1
Time-Dependent  Time-Dependent                Evaluation
     covariate   covariate for  Analysis      Result
    for Week 8         Week 12  Criterion 1   Flag
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              Criterion                 Criterion
              2                         3
              Evaluation                Evaluation
Analysis      Result      Analysis      Result      Analysis
Criterion 2   Flag        Criterion 3   Flag        Criterion 4
Criterion
4
Evaluation  Analysis  Analysis  Analysis
Result      Record    Record    Record
Flag        Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1983-1001                    
19831001                                          
1983                  USA      1999-03-17          23  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               19831001/23/
                                                    F/W         
23/F             23/W/F      
Hispanic or Latino                                          1
    76.2     152.4      32.8  2022-04-08  2022-04-08  2022-05-07
2022-07-29  2022-05-07  2022-08-12  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  07MAY2022
29JUL2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1999-03-17  Jesse Carr                     COMPLETED   
12AUG2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2  On-site                      1      1983
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      14         3  Placebo             14       547
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22764     43560  1.9669E9        -8  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1983-1001                    
19831001                                          
1983                  USA      1999-03-17          23  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
WHITE                                               19831001/23/
                                                    F/W         
23/F             23/W/F      
Hispanic or Latino                                          1
    76.2     152.4      32.8  2022-04-08  2022-04-08  2022-05-07
2022-07-29  2022-05-07  2022-08-12  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  07MAY2022
29JUL2022  Y           Y                                 
Y           Y           Y         Y         Y          N        
1999-03-17  Jesse Carr                     COMPLETED   
12AUG2022                                                    
              COMPLETED                                         
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2  On-site                      1      1983
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      14         3  Placebo             14       551
Placebo               3  Placebo               3        12
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22855     42240  1.9747E9        84  PGI         
POST-                3  MODERATE             4        -1
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
       -25         12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1983-1005                    
19831005                                          
1983                  USA      1981-06-04          40  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               19831005/40/
                                                    M/W         
40/M             40/W/M      
Non-Hispanic or Latino                                      2
    77.5     182.8      23.2  2022-05-06  2022-05-06  2022-05-17
2022-08-08  2022-05-17  2022-08-22  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  17MAY2022
08AUG2022  Y           Y                                 
Y           Y           Y         Y         Y          Y        
1981-06-04  Jesse Carr                     COMPLETED   
22AUG2022                                                    
              COMPLETED                                         
                                                          
N          N                                    
Absence                              2  No                 2
No                 2  On-site                      1      1983
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      14         2  JZP150 4 mg         14       547
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22781     43320  1.9683E9        -1  PGI         
POST-                3  MODERATE             3          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1983-1005                    
19831005                                          
1983                  USA      1981-06-04          40  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               19831005/40/
                                                    M/W         
40/M             40/W/M      
Non-Hispanic or Latino                                      2
    77.5     182.8      23.2  2022-05-06  2022-05-06  2022-05-17
2022-08-08  2022-05-17  2022-08-22  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  17MAY2022
08AUG2022  Y           Y                                 
Y           Y           Y         Y         Y          Y        
1981-06-04  Jesse Carr                     COMPLETED   
22AUG2022                                                    
              COMPLETED                                         
                                                          
N          N                                    
Absence                              2  No                 2
No                 2  On-site                      1      1983
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      14         2  JZP150 4 mg         14       551
JZP150 4 mg           2  JZP150 4 mg           2        12
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22865     48480  1.9756E9        84  PGI         
POST-                2  MILD                 3        -1
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
  -33.3333         12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1983-1008                    
19831008                                          
1983                  USA      1984-12-01          37  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               19831008/37/
                                                    M/W         
37/M             37/W/M      
Hispanic or Latino                                          1
    82.5     180.3      25.3  2022-05-25  2022-05-25  2022-06-15
2022-09-06  2022-06-15  2022-09-22  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  15JUN2022
06SEP2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1984-12-01  Jesse Carr                     DISCONTINUED
22SEP2022  LOST TO FU                                        
LOST TO FU    COMPLETED                                         
                                                          
N          N                                    
Absence                              2  No                 2
No                 2  On-site                      1      1983
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      14         2  JZP150 4 mg         14       727
JZP150 4 mg           2  JZP150 4 mg           2         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22810     46020  1.9708E9        -1  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                   12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1983-1008                    
19831008                                          
1983                  USA      1984-12-01          37  YEARS
<=65 years                                                 1
<=45 years                                                 1
M           1
WHITE                                               19831008/37/
                                                    M/W         
37/M             37/W/M      
Hispanic or Latino                                          1
    82.5     180.3      25.3  2022-05-25  2022-05-25  2022-06-15
2022-09-06  2022-06-15  2022-09-22  Dummy Treatment B
B                     Dummy Treatment B  B                   
JZP150 4 mg           2  JZP150 4 mg           2  15JUN2022
06SEP2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1984-12-01  Jesse Carr                     DISCONTINUED
22SEP2022  LOST TO FU                                        
LOST TO FU    COMPLETED                                         
                                                          
N          N                                    
Absence                              2  No                 2
No                 2  On-site                      1      1983
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      14         2  JZP150 4 mg         14       731
JZP150 4 mg           2  JZP150 4 mg           2        12
Week 12             12  Week 12             12  Week 12     
PGI0101    PGI01-Severity                                    
    22894     45480  1.9781E9        84  PGI         
POST-                1  NONE                 4        -3
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
       -75         12               0               0
             0               0                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable                        Subject'
dose of      dose of                          s type
SSRI/SNRI  SSRI/SNRI  Subject's type        of visit
EDC          EDC (N)  of visit                   (N)      SITE
                                            Analysis
                                            Sequence
  site_n      trtn  trt            SITEIDN    Number
                Planned                   Actual  Analysis
Planned       Treatment  Actual        Treatment     Visit
Treatment           (N)  Treatment           (N)       (N)
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                      Analysis
                                        Window
Analysis         Visit                   Visit  Analysis
Visit           Number  Visit              (N)  Window Visit
                                                     Baseline
Parameter                                            Record
Code       Parameter                                 Flag
                     Analysis  Analysis
Analaysis  Analysis     Date/  Relative  Parameter
     Date      Time      Time       Day  Category 1
                                                  Change
Parameter     Analysis  Analysis      Baseline      from
Category 2       Value  Value (C)        Value  Baseline
Percentage   Duration
    Change         of  Time-Dependent  Time-Dependent
      from  Treatment       covariate       covariate
  Baseline   in Weeks      for Week 1      for Week 4
                                              Criterion
                                              1
Time-Dependent  Time-Dependent                Evaluation
     covariate   covariate for  Analysis      Result
    for Week 8         Week 12  Criterion 1   Flag
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              Criterion                 Criterion
              2                         3
              Evaluation                Evaluation
Analysis      Result      Analysis      Result      Analysis
Criterion 2   Flag        Criterion 3   Flag        Criterion 4
Criterion
4
Evaluation  Analysis  Analysis  Analysis
Result      Record    Record    Record
Flag        Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1986-1006                    
19861006                                          
1986                  USA      1982-10-25          39  YEARS
<=65 years                                                 1
<=45 years                                                 1
F           2
BLACK OR AFRICAN AMERICAN                           19861006/39/
                                                    F/B         
39/F             39/B/F      
Non-Hispanic or Latino                                      2
    97.5     167.6      34.7  2022-09-22  2022-09-22  2022-10-12
2022-11-06  2022-10-12  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  12OCT2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1982-10-25  Diane Highum                   ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2                                      1986
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      15         3  Placebo             15       182
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                                    
    22930     45180  1.9812E9         1  PGI         
POST-                4  SEVERE                          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    4               0               0
             1               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

Study Identifier      Unique Subject Identifier
Subject Identifier for the Study
Study Site                     Date/Time               Age
Identifier            Country  of Birth           Age  Units
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 1                                     1 (N)
                                                      Pooled
                                                         Age
                                                       Group
Pooled Age Group 2                                     2 (N)
Sex   Sex (N)
                                                    Subject
                                                    Identifier
                                                    for Study
Race                                                for Listing
Age/Sex          Age/Race/Sex
                                                    Ethnicity
Ethnicity                                                 (N)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                    Baseline
                        Body  Date/Time               Date/Time
Baseline  Baseline      Mass  of             Date of  of First
  Weight    Height     Index  Informed      Informed  Study
    (kg)      (cm)  (kg/m^2)  Consent        Consent  Treatment
Date/Time   Subject     Subject
of Last     Reference   Reference
Study       Start       Stop        Description of
Treatment   Date/Time   Date/Time   Actual Arm
Description of        Description of     Description of
Actual Arm Code       Planned Arm        Planned Arm Code
                Planned                   Actual    Date of
Planned       Treatment  Actual        Treatment      First
Treatment           for  Treatment           for   Exposure
for Period       Period  for Period       Period         to
01               01 (N)  01               01 (N)  Treatment
  Date of
     Last
 Exposure  Safety      Enrolled    PK          PD
       to  Population  Population  Population  Population
Treatment  Flag        Flag        Flag        Flag
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                  Modified  Completed  PTSD
RAND        Screened    Full      Full      Safety     Diagnosis
Population  Population  Analysis  Analysis  Follow-up  History
Flag        Flag        set Flag  Set       Flg        Flag
                                           Discon.
   Date of                                 Early from
 Birth (N)  Investigator Name              Study
  Discon.
    Early
     from
    Study
     Date  Reas. for Disc. Early from Study
Reas. for
Disc. Early
from Study,
Spcy.         Discon.  Early from study Trt.
              Reas. for
Reas. for     Early                                Subject
Disc. of      Discon. from  Date/Time     Date of  Death
Study Trt.    study Trt.    of Death        Death  Flag
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

           Completed
Completed  Efficacy                 Childbearing
Efficacy   Follow-up  Childbearing     Potential
Follow-up  at Week    Potential      for Females
at Week 4  12         for Females            (N)
                                        Subj on      Subj on
                           Concomitant  stable        stable
                                Use of  dose of      dose of
Concomitant Use              SSRI/SNRI  SSRI/SNRI  SSRI/SNRI
of SSRI/SNRI                       (N)  IRT          IRT (N)
Subj on      Subj on
stable        stable                        Subject'
dose of      dose of                          s type
SSRI/SNRI  SSRI/SNRI  Subject's type        of visit
EDC          EDC (N)  of visit                   (N)      SITE
                                            Analysis
                                            Sequence
  site_n      trtn  trt            SITEIDN    Number
                Planned                   Actual  Analysis
Planned       Treatment  Actual        Treatment     Visit
Treatment           (N)  Treatment           (N)       (N)
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                                      Analysis
                                        Window
Analysis         Visit                   Visit  Analysis
Visit           Number  Visit              (N)  Window Visit
                                                     Baseline
Parameter                                            Record
Code       Parameter                                 Flag
                     Analysis  Analysis
Analaysis  Analysis     Date/  Relative  Parameter
     Date      Time      Time       Day  Category 1
                                                  Change
Parameter     Analysis  Analysis      Baseline      from
Category 2       Value  Value (C)        Value  Baseline
Percentage   Duration
    Change         of  Time-Dependent  Time-Dependent
      from  Treatment       covariate       covariate
  Baseline   in Weeks      for Week 1      for Week 4
                                              Criterion
                                              1
Time-Dependent  Time-Dependent                Evaluation
     covariate   covariate for  Analysis      Result
    for Week 8         Week 12  Criterion 1   Flag
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

              Criterion                 Criterion
              2                         3
              Evaluation                Evaluation
Analysis      Result      Analysis      Result      Analysis
Criterion 2   Flag        Criterion 3   Flag        Criterion 4
Criterion
4
Evaluation  Analysis  Analysis  Analysis
Result      Record    Record    Record
Flag        Flag 01   Flag 02   Flag 03
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

JZP150-201            JZP150-201-1990-1003                    
19901003                                          
1990                  USA      1970-12-11          51  YEARS
<=65 years                                                 1
>45 years                                                  2
F           2
WHITE                                               19901003/51/
                                                    F/W         
51/F             51/W/F      
Non-Hispanic or Latino                                      2
    89.5     160.0      34.6  2022-09-22  2022-09-22  2022-10-14
2022-11-06  2022-10-14  2022-11-06  Dummy Treatment C
C                     Dummy Treatment C  C                   
Placebo               3  Placebo               3  14OCT2022
06NOV2022  Y           Y                                 
Y           Y           Y         Y         N          N        
1970-12-11  Jeffrey Ries                   ONGOING     
                                                             
              ONGOING                                           
                                                          
N          N          Y                        1
Absence                              2  No                 2
No                 2                                      1990
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.3.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}
Key Seconda
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

      16         3  Placebo             16       182
Placebo               3  Placebo               3         0
Baseline             0  Baseline             0  Baseline    
PGI0101    PGI01-Severity                            Y       
    22931     44400  1.9813E9        -1  PGI         
POST-                4  SEVERE               4          
TRAUMATIC                                               
STRESS                                                  
DISORDER                                                
(PTSD)                                                  
                    3               0               1
             2               2                          
                                                                
            Y                   Y       
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity; SD: Standard 
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: PGI-S is a 5-point Likert-type rating scale used to a
^S={}Note: The LS means, SEs, LS Mean Diff, 95% CI and p-value h
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
